Literature DB >> 31615761

Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy.

Khaled Romdhane1, Marta Zola1, Alexandre Matet1, Alejandra Daruich1, Martine Elalouf1, Francine Behar-Cohen2, Irmela Mantel3.   

Abstract

PURPOSE: The aim of this study was to evaluate the effect of anti-vascular endothelial growth factor (VEGF) therapy on choroidal neovascularisation (CNV) complicating central serous chorioretinopathy (CSC) using multimodal imaging, and to identify possible predictive factors of the treatment response.
DESIGN: Retrospective study.
METHODS: Data of 27 eyes with CNV complicating CSC treated with anti-VEGF therapy (either ranibizumab or aflibercept) were reviewed. Response to anti-VEGF treatment was evaluated by change in visual acuity, intra/subretinal fluid modifications and CNV changes on optical coherence tomography angiography (OCTA). Univariate and multivariate analyses were performed to identify predictive factors for central retinal thickness (CRT) change and for the relative degree of treatment response (complete, incomplete or absent fluid reduction).
RESULTS: CRT was significantly reduced at 32±15 days after 2.8±1.3 injections (p=0.0004) as was the subretinal fluid (p=0002). Complete fluid resorption was observed in 45% of cases. Best corrected visual acuity did not significantly improve (p=0.18). CNV area (p=0.09) and CNV flow area (p=0.07) did not significantly decrease. No changes in CNV pattern were noted. Univariate analysis identified greater CRT at baseline (p<0.0001), greater amount of subretinal fluid (p<0.0001), a shorter period of retinal fluid (p=0.04) and female gender (p=0.04) as predictors for CRT reduction. After multivariate analysis the factor of greater CRT at baseline (p<0.0001) proved independent. The degree of treatment response was dependent on the size of CNV surface (p=0.05) and flow area (p=0.05) on OCTA in the univariate analysis, and the latter independent after multivariate analysis. In addition, a shorter time period of retinal fluid appeared to play a role (p=0.01 multivariate, p=0.19 univariate).
CONCLUSION: The anti-VEGF response was highly variable and often incomplete, suggesting that CNV was not solely responsible for the fluid accumulation. Predictive factors may guide indication for anti-VEGF in CNV associated with CSC. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  choroid; neovascularisation; retina; treatment other

Mesh:

Substances:

Year:  2019        PMID: 31615761     DOI: 10.1136/bjophthalmol-2019-314625

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  10 in total

1.  Type one macular neovascularization in central serous chorioretinopathy: Short-term response to anti-vascular endothelial growth factor therapy.

Authors:  Raphaël Lejoyeux; Francine Behar-Cohen; Irmela Mantel; Jorge Ruiz-Medrano; Sarah Mrejen; Ramin Tadayoni; Alain Gaudric; Elodie Bousquet
Journal:  Eye (Lond)       Date:  2021-09-28       Impact factor: 4.456

2.  OCT biomarkers related to subthreshold micropulse laser treatment effect in central serous chorioretinopathy.

Authors:  Fang Zheng; Jingliang He; Zhitao Su; Ye Liu; Yufeng Xu; Lei Liu; Panpan Ye
Journal:  BMC Ophthalmol       Date:  2022-06-07       Impact factor: 2.086

3.  Risk factors and characteristics of central serous chorioretinopathy with later development of macular neovascularisation detected on OCT angiography: a retrospective multicentre observational study.

Authors:  Xiaoyin Zhou; Yuki Komuku; Takashi Araki; Hiroto Terasaki; Akiko Miki; Soichiro Kuwayama; Tomo Nishi; Takamasa Kinoshita; Fumi Gomi
Journal:  BMJ Open Ophthalmol       Date:  2022-04

4.  Ranibizumab non-response in pachychoroid neovasculopathy: Effects of switching to aflibercept.

Authors:  Benedikt Schworm; Nikolaus Luft; Leonie F Keidel; Tina R Herold; Armin Wolf; Siegfried G Priglinger; Jakob Siedlecki
Journal:  Sci Rep       Date:  2020-05-21       Impact factor: 4.379

5.  Comparison of Intraocular Cytokine Levels of Choroidal Neovascularization Secondary to Different Retinopathies.

Authors:  Chenyi Liu; Shian Zhang; Xinyi Deng; Yijing Chen; Lijun Shen; Liang Hu; Jianbo Mao
Journal:  Front Med (Lausanne)       Date:  2021-12-21

6.  Changes in Plasma VEGF and PEDF Levels in Patients with Central Serous Chorioretinopathy.

Authors:  Michał Chrząszcz; Weronika Pociej-Marciak; Katarzyna Żuber-Łaskawiec; Bożena Romanowska-Dixon; Marek Sanak; Katarzyna Michalska-Małecka; Mojca Globočnik Petrovič; Izabella Karska-Basta
Journal:  Medicina (Kaunas)       Date:  2021-10-05       Impact factor: 2.430

7.  OCT Angiography Fractal Analysis of Choroidal Neovessels Secondary to Central Serous Chorioretinopathy, in a Caucasian Cohort.

Authors:  Rita Serra; Antonio Pinna; Francine Behar-Cohen; Florence Coscas
Journal:  J Clin Med       Date:  2022-03-06       Impact factor: 4.241

8.  The Efficacy of Anti-VEGF Therapy for Putative or Visible CNV in Central Serous Chorioretinopathy by Optical Coherence Tomography Angiography.

Authors:  Yumeng Zhang; Jingfa Zhang; Xiaodong Sun
Journal:  J Ophthalmol       Date:  2022-09-28       Impact factor: 1.974

9.  Optical coherence tomography angiography of flat irregular pigment epithelial detachments in central serous chorioretinopathy.

Authors:  Tingting Liu; Wei Lin; Shuping Zhou; Xiangjuan Meng
Journal:  Br J Ophthalmol       Date:  2020-04-07       Impact factor: 4.638

Review 10.  Applications of Multimodal Imaging in Central Serous Chorioretinopathy Evaluation.

Authors:  Mary Ho; Gabriel Li; Andrew Mak; Danny Ng; Lawrence Iu; Frank Lai
Journal:  J Ophthalmol       Date:  2021-07-24       Impact factor: 1.909

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.